Quick Links: Skip to main page content
Skip to Search
Skip to Topics Menu
Skip to Common Links
U.S. Food & Drug Administration
Follow FDA
En Español
Search FDA
Home
Food
Drugs
Medical Devices
Radiation-Emitting Products
Vaccines, Blood & Biologics
Animal & Veterinary
Cosmetics
Tobacco Products
New Pediatric Labeling Information Database - Detail
FDA Home
Pediatrics
New Pediatric Labeling Information Database
Detail
-
Please note:
JavaScript must be enabled for this application to work properly.
Check your settings
if you are unsure if your JavaScript is enabled.
Pediatric Labeling Date:
01/27/2016
Trade Name:
Adzenys XR-ODT
Generic Name or Proper Name (*):
amphetamine
Indications Studied:
Attention Deficit Hyperactivity Disorder in pediatric patients 6 to 17
Label Changes Summary:
* Safety and effectiveness have been established in pediatric patients 6 to 17 years in three clinical trials of up to 4 weeks in duration * Safety and efficacy in pediatric patients younger than 6 years of age have not been established. *Growth should be monitored during treatment with stimulants, including Adzenys XR-ODT, in pediatric patients 6 to 17 years who are not growing or gaining weight as expected because they may need to have their treatment interrupted. *Pediatric patients ages 6 to 12 years: Most common adverse reactions were loss of appetite, insomnia, abdominal pain, emotional lability, vomiting, nervousness, nausea, and fever. Pediatric patients ages 13 to 17 years: Most common adverse reactions were loss of appetite, insomnia, abdominal pain, weight loss, and nervousness. *Information on dosing, adverse reactions, and clinical trials *New dosage form
Product Labeling:
Labeling
PREA(P):
P
Sponsor:
Neos Therapeutics, Inc.
NNPS:
FALSE
Therapeutic Category:
CNS Stimulent
-
-